ANZGOG’s ADELE study is a randomised phase 2 trial that aims to improve outcomes for women with high-risk endometrial cancer. Led by Principal Investigator Prof Linda Mileshkin & co-chair Dr Yeh Chen Lee, the study is testing the effect of ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer: a randomised phase 2 trial.

свернуть